Sublingual Methadone for the Management of Cancer-Related Procedure Pain in Inpatients

Condition(s) targeted: Cancer; Pain

Intervention: Sublingual Methadone (Drug)

Phase: Phase 2

Status: Not yet recruiting

Sponsored by: Alberta Cancer Board

Official(s) and/or principal investigator(s):
Neil Hagen, MD, Principal Investigator, Affiliation: Alberta Cancer Board

Overall contact:
Carla Stiles, Project/Nursing Manager, Phone: 403-210-8423, Email: carlasti@cancerboard.ab.ca

The purpose of this Phase II study is to determine the feasibility of the dose titration and assessment protocol in the impatient population, in the clinical setting of preventing or managing breakthrough pain, before conducting an appropriately powered phase III study. Thus the primary purpose of this study is to determine the proportion of patients who are successfully titrated to an effective dose of sublingual methadone.

Official title: Sublingual Methadone for the Management of Cancer-Related Procedure Pain in Inpatients: a Phase II Multicenter, Open Label, Feasibility Study

Study design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

Primary outcome:

to demonstrate the feasibility of a novel model to assess sublingual methadone to relieve iatrogenic,

treatment related incident breakthrough pain.

Secondary outcome:

to develop a model of PK/PD study of breakthrough pain

to develop a research tool

the Breakthrough Pain Assessment Tool (BPAT)

and to demonstrated proof of concept

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Pain due to cancer or its treatment; Controlled baseline pain; episodes of

predictable, treatment related pain every day that are 4"/10" in severity or greater, last 10 minutes or longer, or episodes of breakthrough pain not related to cancer treatment, and are responsive to short acting oral opioids such as morphine or hydromorphone; are able to hold a volume of 1. 0cc of water under tongue for a 2-minute period; are able to provide written informed consent; are able to fill out the study forms, and are inpatients

Exclusion Criteria:

- Severe underlying respiratory disease such that the investigator is wary about the

risk of respiratory failure from modest doses od opioid; prior sensitivity to methadone; currently are being administered methadone; are clinically unstable or have a life expectancy of less than one month making completion of the trial unlikely; and if they do not understand English sufficiently to provide written informed consent.

Carla Stiles, Project/Nursing Manager, Phone: 403-210-8423, Email: carlasti@cancerboard.ab.ca

Tom Baker Cancer Center, Calgary, Alberta T2N 4N2, Canada; Not yet recruiting
Rachel Syme, PhD, Phone: 403-521-3388, Email: rachelsy@cancerboard.ab.ca

Last updated: July 12, 2006